Drug intelligence / Profile preview

PTD4-apoptin

Development stage
Preclinical
Lead developer
Huazhong University of Science and Technology
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration
Topical
01

Overview

**PTD4-apoptin** is an experimental tumor-selective recombinant fusion-protein therapeutic comprising protein transduction domain 4 fused to apoptin, the VP3 protein of chicken anemia virus. PTD4 promotes cellular uptake, while apoptin preferentially accumulates in the nuclei of transformed cells, where it induces cell-cycle disruption and apoptotic cell death; in normal cells it is predominantly retained in the cytoplasm and is substantially less cytotoxic. The asset has shown antitumor activity in preclinical hepatocellular carcinoma, melanoma, cervical carcinoma, and gastric carcinoma models, including synergy with dacarbazine in melanoma models. ([europepmc.org](https://europepmc.org/article/MED/19326452))

Other names
protein transduction domain 4-apoptin fusion proteinPTD4 + apoptinPTD4-ApoptinPTD-4-ApoptinPTD 4-ApoptinPTD4-apoptin fusion proteinPTD-4-apoptin fusion proteinPTD 4-apoptin fusion proteinPTD4-apoptin proteinPTD-4-apoptin proteinPTD 4-apoptin proteinPTD4-CAV VP3 fusion proteinPTD-4-CAV VP3 fusion proteinPTD 4-CAV VP3 fusion protein
02

Targets

AIFM1 (Apoptosis-inducing factor mitochondria-associated 1)AKT (RAC-alpha serine/threonine-protein kinase)APAF1 (Apoptotic protease-activating factor 1)BCL-2 (BCL-2 family)BCL10 (B-cell lymphoma/leukemia 10 protein)CYCS (Cytochrome c)RYBP (RING1 and YY1-binding protein)FADDNR4A1 (Nuclear receptor subfamily 4 group A member 1)ANAPC1 (APC1)

Beyond the preview

Go deeper on PTD4-apoptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTD4-apoptin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call